Abstract
Study Objective Cannabidiol (CBD) is increasingly used as a health supplement, though few human studies have shown benefits. The primary objective of this study was to evaluate the effects of an oral CBD-Terpene formulation on sleep physiology in insomniacs.
Methods In this pilot study, six participants with insomnia completed a placebo-controlled trial of an oral administration of CBD (300 mg) and terpenes (1 mg each of linalool, myrcene, phytol, limonene, α-terpinene, α-terpineol, α-pinene, and β-caryophyllene), administered daily for 28 days using a cross-over design. Importantly, the study medication was devoid of Δ9-Tetrahydrocannabinol (Δ9-THC). The primary outcome measure was the percentage of time spent in slow wave sleep (SWS) and rapid eye movement (REM) sleep stages, as as measured by a wrist-worn sleep-tracking device.
Results This CBD-terpene regimen increased both the percentage of time (11.9 ± 1.9%; 95% CI, 8.0 to 15.8%; P < 0.0001) and the absolute time (51.8 ± 8.9 min/night; 95% CI, 34.3 to 69.3; P < 0.0001) participants spent in SWS and REM sleep. This treatment had no effect on total sleep time (TST) and no adverse events were reported.
Conclusion These results, if confirmed in larger clinical trials, suggest that select CBD-terpene ratios that increase SWS + REM (restorative) sleep have the potential to provide a safe and efficacious alternative to commonly prescribed sleep medications.
Statement Of Significance Physicians are increasingly asked by their patients regarding the merits of using CBD for insomnia and other ailments, but lack any rigorous clinical research to support recommending its use. The current pilot study represents the first randomized, placebo-controlled, crossover study to investigate how an oral formulation of cannabidiol (CBD) and terpenes influences sleep physiology in participants who suffer from insomnia. In contrast to many prescription sleep medicines and over-the-counter sleep aids, the CBD-terpene formulation increased SWS and REM sleep, which are critical for the immune system, tissue regeneration, cognition and memory. These results, if confirmed in larger clinical trials, suggests that CBD might offer a promising alternative to other sleep medications and aids.
Competing Interest Statement
Michael Wang, Marcus Faust, Scott Abbott, Vikrant Patel, Eric Chang and Dr. Paul Muchowski hold equity in Defined Research Inc., a for-profit company. Dr. John Clark and Dr. Nephi Stella are unpaid consultants who hold stock options for equity in Defined Research Inc. Funding for this study was provided by Defined Research, Inc.
Clinical Trial
ClinicalTrials.gov Identifier: NCT05233761
Funding Statement
This study was funded by Defined Research, Inc., a for-profit biotechnology company.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board Allendale Institutional Review Board, Lyme, Connecticut.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
